PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schmitz, T.* ; Wein, B.* ; Heier, M. ; Peters, A. ; Meisinger, C.* ; Linseisen, J.*

Baseline fibroblast growth factor 23 is associated with long-term mortality in ST-elevation myocardial infarction-results from the augsburg myocardial infarction registry.

Front. Cardiovasc. Med. 10:1173281 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: The aim of this study was to investigate the association between inflammatory plasma protein concentrations and long-term mortality in patients with ST-elevation myocardial infarction (STEMI). METHODS: For 343 STEMI patients recorded between 2009 and 2013 by the population-based Myocardial Infarction Registry Augsburg, 92 inflammatory plasma proteins were measured at the index event using the OLINK inflammation panel. In multivariable-adjusted Cox regression models, the association between each plasma protein and all-cause long-term mortality was investigated. Median follow-up time was 7.6 (IQR: 2.4) years. For plasma protein that showed a strong association with long-term mortality, a 5-year survival ROC analysis was performed. RESULTS: One plasma protein, namely Fibroblast Growth Factor 23 (FGF-23), was particularly well associated with long-term mortality in the multivariable-adjusted Cox model with an FDR-adjusted p-value of <0.001 and a Hazard Ratio (HR) of 1.57 [95% CI: 1.29-1.91]. In the 5-years ROC analysis, an AUC of 0.6903 [95% CI: 0.594-0.781] was estimated for FGF-23. All other plasma protein didńt show strong associations, each marker with FDR-adjusted p-values >0.05 in the multivariable-adjusted Cox models. CONCLUSIONS: FGF-23 is independently associated with long-term mortality after STEMI and might play an important role in the response to myocardial injury. The results suggest FGF-23 to be a useful marker in the long-term treatment of STEMI patients and a potential target for drug development.
Impact Factor
Scopus SNIP
Altmetric
3.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Fgf-23 ; Stemi ; Inflammatory Plasma Protein ; Long-term Mortality ; Myocardial Infarction; Cardiovascular Events; Heart-failure; Ami-registry; Fgf23; Disease; Risk; Fgf-23; Monica/kora; Population; Biomarkers
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2297-055X
e-ISSN 2297-055X
Zeitschrift Frontiers in Cardiovascular Medicine
Quellenangaben Band: 10, Heft: , Seiten: , Artikelnummer: 1173281 Supplement: ,
Verlag Frontiers
Verlagsort Lausanne
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504090-001
G-504000-006
G-504000-010
Förderungen Medical Faculty of the University of Augsburg
BMBF (German Ministry of Education and Research)
DZHK (German Centre for Cardiovascular Research)
German Federal Ministry of Health
State of Bavaria
Helmholtz Zentrum Muenchen, German Research Center for Environmental Health - German Federal Ministry of Education, Science, Research and Technology
DOI 10.3389/fcvm.2023.1173281
WOS ID 001050185200001
Scopus ID 85168334416
PubMed ID 37600039
Erfassungsdatum 2023-10-06
[➜Korrektur melden]